[1] PEGRAM M D,BORGES V F,IBRAHIM N,et al.Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer[J].Breast Cancer Res,2009,11(5):R73.DOI:10.1186/bcr2409.
[2] BURCHELL J M,MUNGUL A,TAYLOR-PAPADIMITRIOU J.O-Linked glycosylation in the mammary gland:changes that occur during malignancy[J].J Mammary Gland Biol Neoplasia,2001,6(3):355-364.DOI:10.1023/A:1011331809881.
[3] RöTTGER S,WHITE J,WANDALL H H,et al.Localization of three humanpolypeptide GalNAc-transferases in HeLa cells suggests initiation of O-linked glycosylation throughout the Golgi apparatus[J].J Cell Sci,1998,111(Pt1):45-60.DOI:10.1242/jeb.01346.
[4] PERRINE C L,GANGULI A,WU P,et al.Glycopeptide-preferring polypeptide GalNAc transferase 10(ppGalNAc T10),involved in mucin-type O-glycosylation,has a unique GalNAc-O-Ser/Thr-binding site in its catalytic domain not found in ppGalNAc T1 or T2[J].J Biol Chem,2009,284(30):20387-20397.DOI:10.1074/jbc.M109.017236.
[5] TEN HAGEN K G,FRITZ T A,TABAK L A.All in the family:the UDP-GalNac:polypeptide N-acetylgalactosaminyltransferases[J].Glycobiology,2003,13(1):1R-16R.DOI:10.1093/glycob/cwg007.
[6] 沈宏杰,吴士良.多肽:N-乙酰氨基半乳糖转移酶的结构和特性[J].生命的化学,2004,24(6):472-474.DOI:10.3969/j.issn.1000-1336.2004.06.009. SHEN Hongjie,WU Shiliang.Structure and characteristic of polypeptide:N-acetylgalactosaminyltransferases[J].Chemistry of Life,2004,24(6):472-474.DOI:10.3969/j.issn.1000-1336.2004.06.009.
[7] 郭晓丹,吴琛,康现江.UDP-GalNAc:多肽N-乙酰氨基半乳糖转移酶-14[J].生命的化学,2010,30(1):27-32. GUO Xiaodan,WU Chen,KANG Xianjiang. UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 14[J].Chemistry of Life,2010,30(1):27-32.
[8] SHIBAO K,IZUMI H,NAKAYAMA Y,et al.Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma[J].Cancer,2002,94(7):1939-1946.DOI:10.1002/cncr.10423.
[9] OLAUSON H,KRAJISNIK T,LARSSON C,et al.A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome[J].Eur J Endocrinol,2008,158(6):929-934.DOI:10.1530/EJE-08-0011.
[10] GOK F,CHEFETZ I,INDELMAN M,et al.Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemiasyndrome[J].Acta Orthop,2009,80(1):131-134.DOI:10.1080/17453670902807482.
[11] BEROIS N,MAZAL D,UBILLOS L,et al.UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker[J].J Histochem Cytochem,2006,54(3):317-328.DOI:10.1369/jhc.5A6783.2005.
[12] FREIRE T,BEROIS N,SOÑORA C,et al.UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6(ppGalNAc-T6)mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells[J].Int J Cancer,2006,119(6):1383-1388.DOI:10.1002/ijc.21959.
[13] PARK J H,NISHIDATE T,KIJIMA K,et al.Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis[J].Cancer Res,2010,70(7):2759-2769.DOI:10.1158/0008-5472.CAN-09-3911.
[14] BEROIS N,BLANC E,RIPOCHE H,et al.ppGalNAc-T13:a new molecular marker of bone marrow involvement in neuroblastoma[J].Clin Chem,2006,52(9):1701-1712.DOI:10.1373/clinchem.2006.067975.
[15] 岳爱环,行书丽,唐春花,等.N-乙酰氨基半乳糖转移酶2对胃癌细胞SGC7901黏附迁移能力的影响[J].江苏大学学报(医学版),2008,18(3):223-226.DOI:10.3969/j.issn.1671-7783.2008.03.010. YUE Aihuan,XING Shuli,TANG Chunhua,et al.Polypeptide:Nacetylgalactosaminyltransferase2’s role during adhesion and migration of gastric cancer cell SGC7901 at cell level[J].Journal of Jiangsu University(Medicine Edition),2008,18(3):223-226.DOI:10.3969/j.issn.1671-7783.2008.03.010.
[16] WU Y M,LIU C H,HU R H,et al.Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor[J].Cancer Res,2011,71(23):7270-7279.DOI:10.1158/0008-5472.CAN-11-1161.
[17] WANG H,TACHIBANA K,ZHANG Y,et al.Cloning and characterization of a novel UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase,pp-GalNAc-T14[J].Biochem Biophys Res Commun,2003,300(3):738-744.DOI:0.1016/S0006-291X(02)02908-X.
[18] WU C,YAO G,ZOU M J,et al.N-Acetylgalactosaminyltransferase 14,a novel insulin-like growth factor binding protein-3 binding partner[J].Biochem Biophys Res Commun,2007,357(2):360-365.DOI:10.1016/j.bbrc.2007.03.153.
[19] WU C,SHAN Y J,LIU X X,et al.GalNAc-T14 may be involved in the regulation of apoptotic action of IGFBP-3[J].J Biosci,2009,34(3):389-395.DOI:10.1007/s12038-009-0045-z.
[20] WU C,GUO X D,WANG W N,et al.UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-14 as a potential new immunohistochemical marker for breast cancer[J].BMC Cancer.2010,10:123.DOI:10.1186/1471-2407-10-123.
[21] 吴琛,田焕娜,王媛媛,等.GALNT14对人乳腺癌MCF-7细胞迁徙的影响[J].中国生物工程杂志,2012,32(7):8-15. WU Chen,TIAN Huanna,WANG Yuanyuan,et al.Effect of GALNT14 on the migration of Human breast cancer cells MCF-7[J].China Biotechnology,2012,32(7):8-15.
[22] KARIN M,RJCHARDS R I.Human metallothionein genes-primary structure of the metallothionein-lI gene and a related processed gene[J].Nature,1982,299(5886):797-802.DOI:10.1038/299797a0.
[23] KARIN M.Metallothionelns:protons in search of function[J].Cell,1985,41(1):9-10.DOI:10.1016/0092-8674(85)90051-0.
[24] BREMNER I.Nutritional and physiological significance of metallothionein[J].Experientia Suppl,1987,52:81-107.DOI:10.1007/978-3-0348-6784-9_5.
[25] NATH R,KAMBADUR R,GULATI S,et al.Molecular aspects,physiologieal function,and clinical significance ofmetallothioneins[J].Crit Rev Food Sci Nutr,1988,27(1):41-85.DOI:10.1080/10408398809527477.
[26] NORDBERG G F.Modulation of metal toxieity by metallothionein[J].Biol Trace Elem Res,1989,21:131-135.DOI:10.1007/BF02917245.
[27] SATO M,BREMNER I.Oxygen free radicals and metallothionein[J].Free Radic Biol Med,1993,14(3):325-333.DOI:10.1016/0891-5849(93)90029-T.
[28] HUSSAIN S,SLIKKER W J,ALI S F.Role of metallothionein and other antioxidants in scavenging superoxide radicals and their possible role in neuroprotection[J].Neurochem Int,1996,29(2):145-152.DOI:10.1016/0197-0186(95)00114-X.
[29] SHIMODA R,ACHANZAR W E,QU W,et a1.Metallothionein is a potential negative regulator of apoptosis[J].Toxieol Sei,2003,73(2):294-300.DOI:10.1093/toxsci/kfg095.
[30] CHERIAN M G,APOSTOLOVA M D.Nuclear localization of metallothionein during cell proliferation and differentiation[J].Cell Mol Biol(Noisy-le-grand),2000,46(2):347-356.
[31] SATOH M,CHERIAN M G,LMURA N,et al.Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis[J].Cancer Res,1994,54(20):5255-5257.
[32] JIN R,CHOW V T,TAN P H,et al.Metallothionein 2A expression is associated with cell proliferation in breast caner[J].Carcinogenesis,2002,23(1):81-86.DOI:10.1093/carcin/23.1.81.
[33] JIN R,BAY B H,CHOW V T,et a1.Significance of metallothionein expression in breast myoepithelial cells[J].Cell Tissue Res,2001,303(2):221-226.DOI:10.1007/s004410000310.
[34] BOON-HUAT B,RONGXIAN J,ANITA J.Analysis of metallothionein expression in human cancers[J].Acta Histochem Cytoc,2001,34(3):171-176.DOI:10.1267/ahc.34.171.
